Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adverse Events
Biotech
Boehringer places ph. 1 study on hold to examine ‘safety event’
Boehringer has suspended a phase 1 trial of an investigational oral small molecule drug in Japan while it seeks to understand a “safety event.”
Marissa Russo
Aug 21, 2026 4:50am
After 2 undisclosed deaths, can China’s IIT still be trusted?
Aug 17, 2026 7:20am
Abivax stock rebounds on colitis prospect safety data
Jun 30, 2026 10:27am
ADA: Tolerability questions linger for Boehringer's obesity drug
Jun 8, 2026 4:30am
ADA: Roche, Zealand make tolerability case for petrelintide
Jun 7, 2026 3:00am
Aardvark halts obesity trials, putting entire pipeline on pause
Mar 24, 2026 4:00am
